Lite Strategy, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Lite Strategy, Inc. (LITS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.72% for the 9-month period ending 2014-03-31, per its 10-Q filed 2014-05-08.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2014-05-08
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2013-09-30 was 1.60%, a 97.75% decline year-over-year.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2012-09-30 was 71.00%, a 5278.79% increase year-over-year.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2011-09-30 was 1.32%.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.01%, a 23.48% decline from fiscal 2012.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2012 was 1.32%, a 17.50% decline from fiscal 2011.
- Lite Strategy, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2011 was 1.60%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2014-03-31 | 1.72% 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | 1.60% 10-Q · filed 2014-02-11 | ||||
| 2013-09-30 | 1.60% 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | 1.01% 10-K · filed 2013-09-18 | ||||
| 2013-03-31 | 0.90% 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | 0.78% 10-Q · filed 2014-02-11 | ||||
| 2012-09-30 | 71.00% 10-Q · filed 2013-11-08 | 0.71% 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | 1.32% 10-K · filed 2013-09-18 | ||||
| 2012-03-31 | 1.32% 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | 1.32% 10-Q · filed 2013-02-12 | ||||
| 2011-09-30 | 1.32% 10-Q · filed 2012-11-13 | ||||
| 2011-06-30 | 1.60% 10-K · filed 2012-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |